Search

Geron Corp

Cerrado

SectorSanidad

1.52 -1.94

Resumen

Variación precio

24h

Actual

Mínimo

1.51

Máximo

1.52

Métricas clave

By Trading Economics

Ingresos

-13M

-17M

Ventas

5.6M

57M

BPA

-0.02

Margen de beneficios

-29.019

Empleados

258

EBITDA

-16M

-12M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+184.87% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

162M

983M

Apertura anterior

3.46

Cierre anterior

1.52

Noticias sobre sentimiento de mercado

By Acuity

75%

25%

317 / 340 Clasificación en Healthcare

Geron Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ago 2026, 19:46 UTC

Geron Corp shares are lower today, reflecting broader market trends, despite remaining above the 20-day moving average and near the upper end of the one-month range.

20 ago 2026, 23:06 UTC

Geron Corp shares are lower in after-market hours, showing notable volatility while remaining above their 20-day moving average and near the month's upper range.

19 ago 2026, 19:26 UTC

Geron Corp shares are higher today, continuing a three-day upward trend. The stock remains above its 20-day moving average, indicating strong market positioning.

18 ago 2026, 21:03 UTC

News

Geron Corporation's shares are lower in after-market trading following the grant of stock options to new employees at an exercise price of $1.53.

17 ago 2026, 23:56 UTC

Geron Corp shares are higher in after-market trading, reflecting notable strength. The stock is significantly above its 20-day moving average.

14 ago 2026, 20:02 UTC

Macro Event

Geron Corp shares are lower today amid broader market declines and disappointing U.S. retail sales data, reflecting negative investor sentiment.

13 ago 2026, 23:36 UTC

Shares of Geron Corp are trading higher in after-market hours, reflecting a strong performance backdrop despite no specific news identified.

12 ago 2026, 23:36 UTC

Geron Corp shares are higher in after-market trading, reflecting an upward move since Wednesday's close. The stock remains above its 20-day moving average.

11 ago 2026, 22:52 UTC

Geron Corp shares are lower in after-market trading with no specific news identified. Broader market sentiment was pressured by rising crude oil prices.

10 ago 2026, 23:06 UTC

Geron Corp shares are higher in after-market hours, reflecting a gain despite mixed market sentiment and geopolitical tensions affecting global energy markets.

7 ago 2026, 20:03 UTC

Geron Corp shares are sharply lower during Friday's trading session, reflecting a broader market decline with no specific news identified to explain the movement.

6 ago 2026, 23:06 UTC

Geron Corp shares traded roughly flat in after-market hours, remaining unchanged since Thursday's close amid a strong recent performance backdrop.

5 ago 2026, 23:31 UTC

Geron Corp shares are lower in after-market hours, continuing a decline that began during regular trading, with no specific news identified.

4 ago 2026, 23:36 UTC

Geron Corp shares are lower in after-market trading, nearing the bottom of their one-month range and below the 20-day moving average.

3 ago 2026, 23:06 UTC

Geron Corp shares are lower in after-market hours, continuing a steady decline since Monday's close and remaining below the 20-day moving average.

31 jul 2026, 20:02 UTC

Geron Corp shares are lower as the Biotechnology sub-sector declines. The stock pulled back from an earlier session high, finishing below its 20-day moving average.

30 jul 2026, 20:56 UTC

Geron Corp shares are higher in after-market hours, influenced by positive corporate earnings amid broader market uncertainty following the Federal Reserve's interest rate decision.

29 jul 2026, 19:32 UTC

Macro Event

Geron Corp shares are lower as market volatility rises following the Federal Reserve's interest rate decision amid ongoing economic growth and inflation concerns.

28 jul 2026, 18:51 UTC

Shares of Geron Corp are lower today amid broader market volatility and uncertainty regarding Federal Reserve decisions. The stock declined since Monday's close.

27 jul 2026, 23:16 UTC

Geron Corp shares are lower in after-market trading, despite earlier gains, with no specific company news driving the decline.

24 jul 2026, 19:46 UTC

Geron Corp shares are lower in Friday's session amid broader market volatility and uncertainty from fluctuating oil prices and new U.S. tariffs.

23 jul 2026, 10:11 UTC

Shares of Geron Corp are higher in pre-market hours, trading above their 20-day moving average. No specific company news was identified.

22 jul 2026, 18:51 UTC

Geron Corp shares are lower today amid broader market trends, as crude oil prices surge due to geopolitical tensions.

21 jul 2026, 23:41 UTC

Geron Corp shares are lower in after-market trading, declining to their lowest point since Tuesday's close. No specific news was identified to explain the drop.

20 jul 2026, 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

Comparación entre iguales

Cambio de precio

Geron Corp previsión

Precio Objetivo

By TipRanks

184.87% repunte

Estimación a 12 Meses

Media 4.33 USD  184.87%

Máximo 6 USD

Mínimo 3 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Geron Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

317 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.